Christine Ring - 02 Jul 2026 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Reporting relationship: Chief Legal Officer
Issuer ticker: NRIX
Reported as of: 02 Jul 2026
Net transaction value: -$259,366
SEC form: 4
Accepted by SEC: 02 Jul 2026, 18:02:59 UTC
Prior SEC filing: 25 Jun 2026
Next SEC filing: 30 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring

Key filing fact

Christine Ring filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 02 Jul 2026.

Key facts

This page summarizes Christine Ring's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Jul 2026, 18:02.

Change

Previous filing in this sequence was filed on 25 Jun 2026.
Current net transaction value: -$259,366.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001817199 Primary reporting owner

Ring Christine

Relationship: Chief Legal Officer
Address: C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE
Signature: /s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring
Signature date: 02 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRIX transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,221
Change %: +38%
Price: $1.86^*
Shares after: 18,800
Date: 02 Jul 2026
Ownership: Direct
Footnotes: F1

NRIX transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,787
Change %: +31%
Price: $8.72^*
Shares after: 24,587
Date: 02 Jul 2026
Ownership: Direct
Footnotes: F1

NRIX transaction

Common Stock

Sale

Transaction value: $259,366
Shares: -11,008
Change %: -45%
Price: $23.56
Shares after: 13,579
Date: 02 Jul 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRIX transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -5,221
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,221
Exercise price: $1.86
Footnotes: F1, F3

NRIX transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -5,787
Change %: -4.3%
Price: $0.000000^*
Shares after: 128,611
Date: 02 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,787
Exercise price: $8.72
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Footnote F2

Represents the weighted average sale price. The lowest price at which shares were sold was $23.23 and the highest price at which shares were sold was $24.16. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Footnote F3

The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Footnote F4

The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.